Modernizing Protein Formulation with Custom Excipients Designed by AI and Robotics

Everyone loves nicely fitted clothing that is tailored to their unique shape.

So do proteins!

At Plexymer, we are challenging the notion that companies should settle with poorly fitted, off-the-shelf polymer excipients that have little specificity to the protein of interest. Plexymer’s proprietary AI-enabled technology allows us to rapidly develop custom fitted excipients for sensitive protein products. Find out more!

A Tailored Approach to Protein Formulation

Proteins deserve better

Why spend so much time engineering proteins only to then add simple, low-performance polymer additives for final formulation? We believe proteins deserve better. At Plexymer, we use artificial intelligence and robotics to tailor make custom polymer excipients that better fit sensitive protein products.

Technology

Plexymer is a Rutgers University startup company based on a platform technology developed in the Gormley Lab. We combine automated combinatorial polymer chemistry and machine learning to develop a streamlined pipeline for data-driven polymer excipient design. Interested customers may simply provide protein, an activity assay, and test conditions and we’ll do the rest without any sponsored project commitment!

Publications

  • Advanced Materials

    Machine learning on a robotic platform for the design of polymer-protein hybrids

  • Advanced Healthcare Materials

    Machine-assisted discovery of chondroitinase ABC complexes towards sustained neural regeneration

  • Cell Reports Physical Science

    Biologic formulation in a self-driving biomaterials lab

  • Nature Reviews Materials

    Machine learning in combinatorial polymer chemistry

  • Advanced Intelligent Systems

    Automation of controlled/living radical polymerization

  • Advanced Drug Delivery Reviews

    Automation and data-driven design of polymer therapeutics

  • ACS Applied Polymer Materials

    Automated PET-RAFT towards pharmaceutical amorphous solid dispersion development

Applications

Meet the Team

  • Glenn Gormley

    Chief Executive Officer

    Former Head of R&D, Executive Chairman & President Daiichi Sankyo, Inc., Global Head of Clinical Development for Novartis, and Chief Medical Officer of Astra Zeneca

  • Matthew Tamasi

    Chief Technology Officer and Co-Founder

    Former Ph.D. Student, Biomedical Engineering, Rutgers University

  • Adam Gormley

    Co-Founder

    Associate Professor, Biomedical Engineering, Rutgers University

Contact us.

Glenn.Gormley@Plexymer.com